BioLineRx Ltd.
| NASDAQ: BLRX | Healthcare / Biotechnology / Israel |
| 1.76 | -0.0600 | -3.30% | Vol 748.94K | 1Y Perf 96.76% |
| Oct 2nd, 2023 16:00 DELAYED |
| BID | 1.68 | ASK | 1.83 | ||
| Open | 1.80 | Previous Close | 1.82 | ||
| Pre-Market | - | After-Market | 1.82 | ||
| - - | 0.06 3.41% |
| Target Price | 9.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 449.43 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 61.21 | Earnings Rating | Strong Sell | |
| Market Cap | 108.29M | Earnings Date | 21st Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.21 | |
| Beta | 1.80 |
Today's Price Range 1.681.83 | 52W Range 0.54502.53 | 5 Year PE Ratio Range -2.90-1.40 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.81% | ||
| 1 Month | -12.87% | ||
| 3 Months | 8.64% | ||
| 6 Months | 82.88% | ||
| 1 Year | 96.76% | ||
| 3 Years | 12.10% | ||
| 5 Years | -91.24% | ||
| 10 Years | -95.62% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -41.02 | |||
ROE last 12 Months | -40.70 | |||
ROA (5Y Avg) | -20.84 | |||
ROA last 12 Months | -30.30 | |||
ROC (5Y Avg) | -47.60 | |||
ROC last 12 Months | -32.28 | |||
Return on invested Capital Q | -10.66 | |||
Return on invested Capital Y | -5.88 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.30 | ||||
| 0.66 | ||||
| - | ||||
| - | ||||
| -1.80 | ||||
| -0.54 | ||||
| 0.66 | ||||
| 0.90 | ||||
| -1 776 950.00 | ||||
| Forward PE | -6.06 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.10 | ||||
| 7.10 | ||||
| 0.15 | ||||
| 0.19 | ||||
| -22.20 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.16 | -0.30 | -87.50 |
| Q01 2023 | -0.14 | -0.15 | -7.14 |
| Q04 2022 | -0.14 | -0.09 | 35.71 |
| Q03 2022 | -0.16 | -0.15 | 6.25 |
| Q02 2022 | -0.14 | -0.16 | -14.29 |
| Q01 2022 | -0.15 | -0.10 | 33.33 |
| Q04 2021 | -0.14 | -0.08 | 42.86 |
| Q03 2021 | -0.13 | -0.23 | -76.92 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.18 | -12.50 | Negative |
| 12/2023 QR | -0.18 | -12.50 | Negative |
| 12/2023 FY | -0.83 | -27.69 | Negative |
| 12/2024 FY | -0.30 | -100.00 | Negative |
| Next Report Date | 21st Nov 2023 |
| Estimated EPS Next Report | -0.18 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 748.94K |
| Shares Outstanding | 61.53K |
| Shares Float | 60.55M |
| Trades Count | 2.47K |
| Dollar Volume | 1.32M |
| Avg. Volume | 1.46M |
| Avg. Weekly Volume | 821.59K |
| Avg. Monthly Volume | 2.44M |
| Avg. Quarterly Volume | 1.12M |
BioLineRx Ltd. (NASDAQ: BLRX) stock closed at 1.76 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 748.94K shares and market capitalization of 108.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. BioLineRx Ltd. CEO is Philip Serlin.
The one-year performance of BioLineRx Ltd. stock is 96.76%, while year-to-date (YTD) performance is 198.31%. BLRX stock has a five-year performance of -91.24%. Its 52-week range is between 0.545 and 2.53, which gives BLRX stock a 52-week price range ratio of 61.21%
BioLineRx Ltd. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 0.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.30%, a ROC of -32.28% and a ROE of -40.70%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioLineRx Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. BioLineRx Ltd.’s next earnings report date is 21st Nov 2023.
The consensus rating of Wall Street analysts for BioLineRx Ltd. is Strong Buy (1), with a target price of $9.67, which is +449.43% compared to the current price. The earnings rating for BioLineRx Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioLineRx Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioLineRx Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.20, ATR14 : 0.20, CCI20 : -132.79, Chaikin Money Flow : -0.17, MACD : 0.06, Money Flow Index : 47.43, ROC : 0.00, RSI : 46.14, STOCH (14,3) : 16.92, STOCH RSI : 0.00, UO : 48.24, Williams %R : -83.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioLineRx Ltd. in the last 12-months were:
BioLineRx Ltd.
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.
CEO: Philip Serlin
Telephone: +972 86429100
Address: 2 HaMa'ayan Street, Modi'in 7177871, , IL
Number of employees: 38
